Live data · NADAC + Part D CY24 · reviewed daily

Lisinopril and Hydrochlorothiazide Tablets (Lisinopril and Hydrochlorothiazide)

Thiazide Diuretic class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2015-03-12
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.029/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.034
Across all dosage forms in distribution.
Highest NADAC
$0.041
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Lisinopril and Hydrochlorothiazide Tablets used for?

Lisinopril and Hydrochlorothiazide Tablets is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Lisinopril and Hydrochlorothiazide Tablets?

No. Lisinopril and Hydrochlorothiazide Tablets is brand-only with no generic equivalents currently in market.

How much does my plan pay for Lisinopril and Hydrochlorothiazide Tablets?

Across 329 Part D plans, Lisinopril and Hydrochlorothiazide Tablets averages $0.034/unit (NADAC). Lowest available: $0.029/unit. Highest in distribution: $0.041/unit.

Is Lisinopril and Hydrochlorothiazide Tablets on the FDA shortage list?

No. Lisinopril and Hydrochlorothiazide Tablets is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.